Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

Stock analysts at initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMDGet Free Report) in a research report issued on Saturday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ TXMD opened at $1.51 on Friday. The company has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $2.16. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $4.35.

TherapeuticsMD (NASDAQ:TXMDGet Free Report) last posted its quarterly earnings results on Friday, May 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. The company had revenue of $0.31 million during the quarter.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMDFree Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned about 2.57% of TherapeuticsMD at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.

Read More

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with's FREE daily email newsletter.